Business Context and Reporting Period
This Form 8-K, filed on January 24, 2022, by Crane Co. (NYSE: CR), reports the results of operations for the quarter ended December 31, 2021. The filing primarily details the Company's ongoing exposure to asbestos-related litigation and provides an update on the estimated liability and insurance recoveries associated with these claims.
Key Financial Metrics: Asbestos Litigation
The filing does not provide consolidated revenue, profit, or cash flow figures for the quarter; these are referenced in an attached press release (Exhibit 99.1). The following metrics relate specifically to asbestos claims and costs:
- Ending Pending Claims (Dec 31, 2021): 29,958 (including approximately 18,000 in New York, of which 16,000 are inactive non-malignancy claims).
- Total Costs Incurred (2021): $55.2 million (Settlement/indemnity: $40.6 million; Defense: $14.6 million).
- Net Pre-tax Cash Payments (2021): $44.9 million (after $13.1 million in insurance receipts).
- Total Estimated Liability (Dec 31, 2021): $612 million (down from $670 million in 2020).
- Current Portion of Liability: $62.3 million (expected to be paid within 12 months).
- Estimated Insurance Recovery Asset (Dec 31, 2021): $74 million (down from $87 million in 2020).
Material Changes Versus Prior Period
- Claim Volume: New claims filed in 2021 totaled 2,975, an increase from 2,620 in 2020. Dismissals decreased to 1,175 in 2021 compared to 1,653 in 2020.
- Costs Incurred: Total asbestos costs incurred rose to $55.2 million in 2021 from $50.9 million in 2020.
- Cash Payments: Net pre-tax cash payments increased significantly to $44.9 million in 2021 from $31.1 million in 2020.
- Liability Estimate: The total recorded asbestos liability decreased by $58 million to $612 million as of December 31, 2021. Management determined no change to the liability estimate was warranted for the period based on actual experience approximating assumptions.
- Insurance Asset: The asset for probable insurance recoveries decreased by $13 million to $74 million.
Outlook, Risks, and Contingencies
Liability Methodology: The Company utilizes an independent actuarial firm to estimate liabilities through 2059. Key factors influencing the estimate include the number of new mesothelioma claims, average settlement costs for mesothelioma, dismissal rates, and aggregate defense costs.
Insurance Coverage: The Company has settled with all but two solvent excess insurers. The model forecasts approximately 14% of the liability will be reimbursed by insurers. The Company notes that cash payments and insurance receipts often lag the recognition of costs.
Risks and Uncertainties: Significant uncertainties remain regarding the timing, severity, and quantity of future claims. Factors such as legislative changes, judicial rulings, and the financial viability of insurers could materially alter the estimated liability and insurance recoveries. The Company cautions that actual costs may differ from estimates.
Investor Verification Checklist
- Verify the full quarterly financial results (Revenue, Net Income, EPS) in the attached Exhibit 99.1 (Earnings Press Release), as this 8-K focuses on litigation.
- Monitor the trend of new mesothelioma claims versus dismissals, as these are primary drivers of the liability estimate.
- Review the status of the two remaining solvent excess insurers with whom the Company has not yet finalized settlement agreements.
- Assess the impact of the $44.9 million net cash outflow for asbestos on the Company's overall liquidity and free cash flow.
- Track any legislative or judicial developments in key jurisdictions (e.g., New York) that could alter the "Dummitt" precedent or claim resolution dynamics.